On 17 November, a roundtable discussion was organised by COMMUTE, an EU-funded project that investigates potential links between COVID-19 and neurodegenerative disease, through both data-driven artificial intelligence (AI) and machine learning and hypothesis -driven approaches. Soraya Moradi-Bachiller, Public Involvement Officer, Alzheimer Europe, participated in the discussion. During the session, the panellists and the members of the COMMUTE consortium explored the ethical and legal implications of AI-enabled predictive tools for clinical authority and the doctor-patient relationship, with a particular focus on Alzheimer’s and Parkinson’s disease. They also discussed how the standards of care, liability, informed consent, trust, communication and decision-making may evolve when patients and clinicians engage with AI.
